Final ALTA-1 results of brigatinib (BRG) and crizotinib (CRZ) in ALK inhibitor-naive non-small cell lung cancer (NSCLC)
Authors
Griesinger, F.Camidge, D. R.
Kim, H. R.
Ahn, M. J.
Yang, J. C.
Han, J. Y.
Hochmair, M.
Lee, K. H.
Delmonte, A.
Garcia, C. M. R.
Kim, D. W.
Felip, E.
Califano, Raffaele
Spira, A.
Thomas, M.
Gettinger, S.
Tiseo, M.
Lin, H.
Liu, Y.
Zhang, P.
Popat, S.
Affiliation
Pius-Hospital Oldenburg, University of Oldenburg, Oldenburg, DeutschlandIssue Date
2022